Figure 7.

Clinical Validation of the Impact of IL-6 and MCP-1 Using Data of the Cohort Study

(A) Gene expression levels of IL6 in the EAT were significantly attenuated in the diabetic patients treated with SGLT2 inhibitor compared to those treated with other antidiabetic drugs. (B) Those of MCP1 was not significantly affected. (C)IL6 mRNA levels in the EAT were significantly increased in the patients with atrial fibrillation compared to those without atrial fibrillation. (D) No significant difference was observed in MCP1 between the 2 groups. (E) Patients with high IL6 expression in EAT have higher plasma NT-proBNP levels. (F) No significant difference was observed in NT-proBNP levels between the patients with high MCP1 expression in EAT and low MCP1 expression in EAT. Data are presented as mean ± SD and compared using the Mann-Whitney U test. ∗P < 0.05. NT-proBNP = N-terminal pro–B-type natriuretic peptide; other abbreviations as in Figures 1, 2, 3, and 4.